This Week in Family Medicine — Oct 4, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Family Medicine. This week we're covering 9 notable papers spanning the fast-moving field of incretin-based metabolic drugs, what body weight does and does not tell us about risk, and conditions that primary care either misses or could treat more simply. Let's dive in.

The incretin pipeline continues to broaden, and four papers this week test newer agents and probe how the established ones work. In the New England Journal of Medicine, Jastreboff and colleagues report the phase 3 trial of retatrutide, a once-weekly injection that acts on three hormone receptors, in 2,339 adults with obesity but without diabetes [1]. Over 80 weeks, participants on the highest dose lost about a quarter of their body weight, against roughly four percent with placebo. In a subgroup with knee osteoarthritis, pain scores fell modestly more than with placebo, and among participants with obstructive sleep apnea, the treated groups had roughly 22 to 25 fewer breathing events per hour than the placebo group. Gastrointestinal effects were the most common adverse events, and the trial was industry funded. Also in the New England Journal of Medicine, Wharton and colleagues tested survodutide, a dual glucagon and GLP-1 receptor agonist, in 752 adults with type 2 diabetes and a body mass index of 27 or more [2]. At 76 weeks, weight fell by about ten percent at the higher dose versus about four percent with placebo, and glycated haemoglobin dropped by close to one point from a fairly well-controlled baseline of 7.4 percent. Gastrointestinal events affected roughly three quarters of treated participants, mostly mild and transient. Read together, these trials suggest that weight loss in people with diabetes remains smaller than in those without, a pattern worth keeping in mind when comparing headline figures across trials.

The most immediately relevant of the group for primary care may be ACHIEVE-4 in The Lancet, led by Klein, which tested orforglipron, an oral, non-peptide GLP-1 receptor agonist, against insulin glargine in 2,749 adults with type 2 diabetes, overweight or obesity, and established cardiovascular or chronic kidney disease [3]. Over a median of two years, major cardiovascular events occurred in about four percent of the orforglipron group and five percent of the insulin group, meeting the prespecified non-inferiority threshold. This is a safety finding, not proof of cardiovascular benefit, and the trial was open label. Severe or clinically significant hypoglycaemia occurred about a third as often with orforglipron, while gastrointestinal adverse events affected about six in ten orforglipron users compared with about one in seven on insulin. Fewer deaths were recorded in the orforglipron arm, 19 versus 43, though mortality was not the primary outcome. Finally, a mechanistic trial in Nature Medicine from Tuttle and colleagues randomised 106 people with type 2 diabetes and chronic kidney disease to semaglutide or placebo for a year [4]. The coprimary imaging measures of kidney oxygenation, perfusion and inflammation did not change significantly. Secondary findings pointed toward lower renal vascular resistance, signs of halted fibrosis progression, and healthier glomerular endothelial cells, but these are exploratory signals that add plausibility rather than new clinical evidence.

Two observational studies this week ask what body mass index tells clinicians, and the answers cut in different directions. In BJGP Open, Duguet and colleagues followed just over ten thousand French children aged 2 to 17 through general practice records [5]. Children with overweight or obesity consulted their general practitioner more often, and within the same child, moving from normal weight to overweight was linked to roughly half again as many consultations, with a further rise of about two thirds on moving into obesity. The design cannot establish why these children consult more, but it frames excess weight in childhood as a measurable workload for primary care, and arguably as a series of contacts where prevention could be addressed. In JAMA, de Avila and colleagues examined over 18 thousand adults with biopsy-proven metabolic dysfunction-associated steatotic liver disease from 41 countries [6]. Only around seven percent of patients were lean, more often in Asia. Lean patients had milder histology and less diabetes, yet once other factors were accounted for, lean status did not predict mortality or liver events. Fibrosis did: advanced fibrosis roughly doubled the risk of death and more than tripled the risk of liver-related clinical events. Notably, the FIB-4 score performed somewhat less well in lean patients, while liver stiffness on transient elastography performed better. The study is retrospective and limited to biopsied patients, so it may not reflect the lower-risk population seen in primary care, but it supports the view that normal weight is not reassurance in fatty liver disease.

The final theme concerns conditions that are either underdiagnosed or could be managed more simply. In The Lancet, the RESOLVE trial led by Goel randomised 880 treatment-naive adults with chronic hepatitis C and no cirrhosis, across five public hospitals in India, to eight or twelve weeks of sofosbuvir-velpatasvir [7]. Cure rates were about 99 percent in both arms in the per-protocol analysis, and the shorter course was non-inferior on intention-to-treat as well, with no treatment discontinuations for adverse events. The population was young, with a median age of 35, and the trial was open label and conducted in one country, so generalisation to older patients or other genotype mixes is not yet established, and guidelines still specify twelve weeks. Still, a shorter course could matter for simplified, community-based hepatitis C treatment. The Prospective Urban Rural Epidemiology study, reported by Duong and colleagues in The Lancet Global Health, performed spirometry on about 119 thousand adults in 25 countries [8]. Roughly one in ten participants had airflow obstruction, and nearly nine in ten of those people had never been diagnosed with an airway disease. Underdiagnosis was more common in younger, less symptomatic people, in never smokers as well as current smokers, and in lower-income countries. Those undiagnosed individuals still had about fifty percent higher mortality and roughly double the respiratory events of people without obstruction, with a smaller rise in cardiovascular events. Whether finding and treating this mostly mild disease improves outcomes was not tested, so the study strengthens the case for case-finding without yet showing it works. Rounding out the week, Nature Reviews Disease Primers carries a review of irritable bowel syndrome from Chang and colleagues [9]. It describes a disorder of gut-brain interaction affecting about four to eleven percent of people worldwide, emphasises a positive, symptom-based diagnosis using the new Rome V criteria with limited testing, and outlines stepwise management through education, diet, medication and gut-brain behavioural therapies. As a narrative review, it synthesises rather than adds new trial evidence.

If you only have time for one paper this week, make it ACHIEVE-4 in The Lancet [3]. It is the first cardiovascular safety evidence for an oral, non-peptide GLP-1 drug in exactly the high-risk diabetes population seen daily in family practice, and it reopens the question of where a pill-based incretin fits relative to injectables and insulin.

Here is what this week's evidence adds up to in Family Medicine. First, newer incretin agents produce substantial weight loss and, for retatrutide, improvements in knee pain and sleep apnea, though these are industry-funded trials without long-term outcome data. Second, oral orforglipron now has randomised evidence of cardiovascular safety against insulin with far less hypoglycaemia, but gastrointestinal intolerance is common and cardiovascular benefit remains unproven. Third, in fatty liver disease, fibrosis rather than body weight tracked with prognosis, and elastography held up better than FIB-4 in lean patients, from retrospective biopsy data. Fourth, a single large trial supports eight weeks of sofosbuvir-velpatasvir in non-cirrhotic, treatment-naive hepatitis C, pending guideline review. Fifth, undiagnosed airflow obstruction is common worldwide and carries real risk, though the benefit of earlier detection is still unsettled.

That's your roundup for This Week in Family Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.